Merck’s (MRK) V114, an investigational 15-valent pneumococcal conjugate vaccine, is under priority review by the FDA, with a decision anticipated on July 18. V114 is proposed for the prevention of invasive pneumococcal disease in adults 18 years of age and older. It consists of pneumococcal polysaccharides from 15 serotypes.Recently, Pfizer’s 20-valent pneumococcal conjugate vaccine, 20vPnC, was granted FDA approval for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged 18 years and older.MRK closed Wednesday’s (Jun.23, 2021) trading at $75.58, down 0.80%.